

In the claims:

Amend claims 8, 28, and 29 as follows:

174
--8. (Amended) The peptide of claim 6, wherein the amino acid sequence is selected from the group consisting of Ala-Gln-Lys-Arg-Arg (SEQ ID NO:124), Gly-Lys-Ser-Arg-Arg (SEQ ID NO:125), Glu-Gln-Lys-Arg-Arg (SEQ ID NO:126), Glu-Ala-Lys-Arg-Arg (SEQ ID NO:127), Gly-Gln-Lys-Arg-Arg (SEQ ID NO:128), Gly-Ala-Lys-Arg-Arg (SEQ ID NO:129), Gly-Lys-Lys-Arg-Arg (SEQ ID NO:130), Gly-His-Lys-Arg-Arg (SEQ ID NO:131), Gly-Lys-Ala-Phe-Arg (SEQ ID NO:132), Glu-Lys-Ala-Gln-Arg (SEQ ID NO:133), and Glu-Lys-Ala-Arg-Arg (SEQ ID NO:134).--

A 15
--28. (Amended) The composition of claim 17, wherein the peptide is Gly-Gly-Lys-Ala-Arg-Arg-Leu (SEQ ID NO:135).--

A 16
--29. (Amended) The composition of claim 17, wherein the therapeutic drug is a compound belonging to the group of thapsigargins which have been derivatized with a moiety containing a primary amine group, the peptide is Gly-Gly-Lys-Ala-Arg-Arg-Leu (SEQ ID NO:135), and the linker is selected from the group consisting of unsubstituted or alkyl-, aryl-, halo-, alkoxy-, alkenyl-, amido- or amino-substituted $\text{CO}-(\text{CH}=\text{CH})_{n1}-(\text{CH}_2)_{n2}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n2}-(\text{CH}=\text{CH})_{n1}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n2}-(\text{CH}=\text{CH})_{n1}-\text{CO}-\text{NH}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}=\text{CH})_{n1}-(\text{CH}_2)_{n2}-\text{CO}-\text{NH}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n3}-\text{NH}_2$, and $\text{CO}-(\text{CH}_2)_{n3}-\text{NH}-\text{CO}-\text{CH}(\text{R}_4)-\text{NH}_2$, wherein $n1$ and $n2$ are from 0 to 5, $n3$ is from 0 to 15, Ar is any substituted or unsubstituted aryl group, attachment of NH_2 to Ar is in a ortho, meta or para position with respect to the remainder of the linker, and R_4 is any naturally occurring amino acid side chain.--